Sociodemographic disparities, such as low income and lack of health insurance, contribute to reduced CRC screening at age 45 years.

Ambulatory acute kidney injury is common among individuals with cirrhosis and is associated with a high 90-day mortality.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis.

Experienced weight stigma improves from pre- to post-metabolic bariatric surgery, according to a recent study.

Early-life factors are associated with body mass index trajectories in children, with risk for obesity detectable at age 3.5 years.